SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff Backs CSL Behring Clot Disorder Therapy

January 7, 2009 | 
1 min read

WASHINGTON, Jan 7 (Reuters) - CSL Ltd’s proposed treatment for a rare bleeding disorder appears safe and effective enough to support approval, U.S. drug reviewers said in documents released on Wednesday.

Regulatory
Food and Drug Administration (FDA) CSL
MORE ON THIS TOPIC
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Government
Congress Re-Introduces EPIC Act to Remove IRA’s ‘Pill Penalty’
February 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration
Neuroscience
Emalex Heads to FDA After Phase III Tourette Syndrome Win
February 26, 2025
 · 
2 min read
 · 
Tristan Manalac